ProCE Banner Activity

Double Vs Single ASCT in Newly Diagnosed Multiple Myeloma: An Analysis of the EMN02/HO95 Phase III Trial

Slideset Download
Conference Coverage
This prospective subanalysis of the phase III EMN02/HO95 trial suggests benefit in PFS and OS with double ASCT, particularly for patients with high-risk MM.

Released: December 14, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology